Conditions: Neuroendocrine Tumors; Carcinoid Tumor
Intervention: Drug: RAD001 (everolimus, Afinitor®)
Sponsors: Guangdong General Hospital; Novartis
Active, not recruiting - verified May 2010
Feeds
4318 items (4318 unread) in 87 feeds
Acinar Cell Carcinoma
(24 unread)
Acinic Cell Carcinoma
(33 unread)
Adenoid Cystic Carcinoma
(83 unread)
Adrenal Gland Cancer
(305 unread)
Ampulla Of Vater
(23 unread)
Anal Cancer
(212 unread)
Angiosarcoma
(79 unread)
Appendix Cancer
(66 unread)
Bile Duct Cancer
(332 unread)
Brain and CNS
(1194 unread)
Carcinoid
(124 unread)
Endocrine/Neuroendocrine
(500 unread)
Gall Bladder Cancer
(89 unread)
General
(4 unread)
Hemangioendothelioma
(38 unread)
HemeOnc
(78 unread)
Hepatoblastoma
(46 unread)
Pancreas
(76 unread)
Phyllodes
(21 unread)
PMP and Mucinous Tumors
(35 unread)
Rhabdomyosarcoma
(175 unread)
Sarcoma
(313 unread)
Twitter Pals
(468 unread)
Trials - Carcinoid (42 unread)
-
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Posted: August 2nd, 2010, 9:00am CDT
-
Study of Panitumumab in the Treatment of Carcinoid Syndrome
Posted: July 28th, 2010, 9:00am CDT
Condition: Carcinoid Syndrome
Intervention: Drug: Panitumumab
Sponsors: Boston Medical Center; Amgen
Not yet recruiting - verified July 2010 -
Hypofractionated Proton Radiation Therapy
Posted: July 16th, 2010, 9:00am CDT
Conditions: Non-small Cell Lung Cancer; Small Cell Lung Cancer; Carcinoid; Thymic Cancer; Lung Cancer
Intervention: Radiation: Proton Therapy
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified July 2010 -
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Posted: June 30th, 2010, 9:00am CDT
Conditions: Extensive Stage Small Cell Lung Cancer; Hereditary Paraganglioma; Male Breast Cancer; Malignant Paraganglioma; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Pheochromocytoma; Pancreatic Polypeptide Tumor; Recurrent Breast Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Neuroendocrine Carcinoma of the Skin; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pheochromocytoma; Recurrent Prostate Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Regional Gastrointestinal Carcinoid Tumor; Regional Pheochromocytoma; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Neuroendocrine Carcinoma of the Skin; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Prostate Cancer; Stage III Renal Cell Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Endometrial Carcinoma; Stage IV Neuroendocrine Carcinoma of the Skin; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer; Thyroid Gland Medullary Carcinoma
Interventions: Drug: temsirolimus; Drug: vinorelbine ditartrate
Sponsor: USC/Norris Comprehensive Cancer Center
Recruiting - verified June 2010 -
Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Posted: April 12th, 2010, 9:00am CDT
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start); Drug: Mid-low dose LX1606 - Day 15 (start); Drug: Mid-high dose LX1606 - Day 29 (start); Drug: High dose LX1606 - Day 43 (start); Drug: Open Label Dose Extension
Sponsor: Lexicon Pharmaceuticals
Recruiting - verified June 2010 -
Seneca Valley Virus-001 in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
Posted: January 13th, 2010, 9:00am CST
Conditions: Adrenocortical Carcinoma; Gastrointestinal Carcinoid Tumor; Kidney Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: Seneca Valley virus-001; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010 -
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Posted: December 1st, 2009, 9:00am CST
Conditions: Neuroendocrine Tumor; Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Intervention: Drug: AMG 479
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; H. Lee Moffitt Cancer Center and Research Institute; Amgen
Recruiting - verified August 2010 -
Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Posted: November 24th, 2009, 9:00am CST
Condition: Carcinoid Syndrome
Intervention: Drug: BIM 23A760
Sponsor: Ipsen
Recruiting - verified July 2010 -
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor
Posted: November 6th, 2009, 9:00am CST
Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2010 -
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Posted: August 24th, 2009, 9:00am CDT
Conditions: Thymoma; Thymic Carcinoma; Thymic Carcinoid; Thymic Neuroendocrine Tumors
Intervention: Drug: IMA12
Sponsor: National Cancer Institute (NCI)
Recruiting - verified May 2010 -
Azilect + Antidepressant Chart Review
Posted: August 6th, 2009, 9:00am CDT
Condition: Serotonin Syndrome
Interventions: Drug: Group R+AD Rasagiline + Antidepressant; Drug: Group R Rasagiline; Drug: Group AD Anti-PD + Antidepressant
Sponsor: Teva Pharmaceutical Industries
Completed - verified June 2010 -
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Posted: July 23rd, 2009, 9:00am CDT
Conditions: Neuroendocrine Tumors; Neuroendocrine Tumors Carcinoid Tumors; Neuroendocrine Tumors Islet Cell Tumors (Pancreatic Neuroendocrine Tumors); Neuroendocrine Tumors Adrenal Gland Tumors; Neuroendocrine Tumors Multiple Endocrine Neoplasia, Type 1/2; Neuroendocrine Tumors Neuroblastoma
Interventions: Drug: pertuzumab; Drug: erlotinib
Sponsors: Stanford University; Genentech
Recruiting - verified June 2010 -
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Posted: July 17th, 2009, 9:00am CDT
Conditions: Neuroendocrine Tumor; Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Interventions: Drug: Sorafenib; Drug: RAD001
Sponsors: Dana-Farber Cancer Institute; Novartis; Bayer
Active, not recruiting - verified August 2010 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Posted: May 15th, 2009, 9:00am CDT
Conditions: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Nausea and Vomiting; Pancreatic Cancer; Peritoneal Cavity Cancer; Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010 -
Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Posted: February 25th, 2009, 9:00am CST
Condition: Carcinoid Syndrome
Interventions: Drug: Low Dose Part 1; Drug: Mid-Low Dose Part 1; Drug: Mid-High Dose Part 1; Drug: High Dose Part 1; Drug: Part 2 Expanded Cohort; Drug: Placebo; Drug: Open Label Dose Extension; Drug: Open Label Extension 2
Sponsor: Lexicon Pharmaceuticals
Recruiting - verified August 2010 -
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Posted: December 5th, 2008, 9:00am CST
Conditions: Neuroendocrine Tumor; Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Interventions: Drug: SOM230; Drug: RAD001
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital; Faulkner Hospital; Novartis
Recruiting - verified August 2010 -
Multicenter Study of IMC-A12 in Combination With Depot Octreotide in Patients With Carcinoid or Islet Cell Cancer
Posted: October 27th, 2008, 9:00am CDT
Conditions: Carcinoma; Neuroendocrine Tumors
Intervention: Biological: A12
Sponsor: ImClone LLC
Recruiting - verified July 2010 -
An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Posted: October 15th, 2008, 9:00am CDT
Condition: Carcinoid Syndrome
Interventions: Drug: lanreotide; Drug: placebo
Sponsor: Ipsen
Recruiting - verified July 2010 -
Optical Coherence Tomography of the Airway in Detecting Abnormal Cells in Patients Undergoing Surgery for Lung Cancer or Lung Disease
Posted: August 12th, 2008, 9:00am CDT
Conditions: Lung Cancer; Malignant Mesothelioma; Metastatic Cancer; Nonmalignant Neoplasm; Precancerous Condition
Interventions: Procedure: bronchoscopic and lung imaging studies; Procedure: diagnostic bronchoscopy; Procedure: histopathologic examination; Procedure: optical coherence tomography
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2010 -
Somatuline Autogel Preference and Health Economy Study
Posted: May 19th, 2008, 9:00am CDT
Condition: Neuroendocrine Tumour With Carcinoid Symptoms
Intervention: Drug: Lanreotide Autogel
Sponsor: Ipsen
Active, not recruiting - verified July 2010 -
ChemoFx® PRO - A Post-Market Data Collection Study
Posted: April 25th, 2008, 9:00am CDT
Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsor: Precision Therapeutics
Recruiting - verified August 2010 -
Natural History of Familial Carcinoid Tumor
Posted: March 26th, 2008, 9:00am CDT
Condition: Carcinoid
Intervention:
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2010 -
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Posted: December 5th, 2007, 9:00am CST
Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010 -
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Posted: October 1st, 2007, 9:00am CDT
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008 -
Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic
Posted: September 20th, 2007, 9:00am CDT
Conditions: Cognitive/Functional Effects; Delirium; Esophageal Cancer; Head and Neck Cancer; Lung Cancer
Interventions: Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified August 2010 -
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Posted: April 25th, 2007, 9:00am CDT
Conditions: Head and Neck Cancer; Islet Cell Tumor; Metastatic Cancer; Pheochromocytoma
Interventions: Drug: octreotide acetate; Radiation: yttrium Y 90 resin microspheres
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified July 2010 -
Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer
Posted: March 27th, 2007, 9:00am CDT
Conditions: Islet Cell Tumor; Lung Cancer; Multiple Endocrine Neoplasia
Intervention: Drug: Pazopanib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified June 2010 -
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Posted: March 1st, 2007, 9:00am CST
Condition: Neuroendocrine Tumors
Intervention: Drug: High Dose Indium-111 pentetreotide (Neuroendomedix)
Sponsors: Radio Isotope Therapy of America; Excel Diagnostic Imaging Clinics; RadioMedix; St. Luke's Episcopal Hospital, Texas
Recruiting - verified July 2010 -
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
Posted: February 9th, 2007, 9:00am CST
Conditions: Neuroendocrine Tumor; Islet Cell Tumor
Interventions: Drug: Sunitinib malate; Procedure: Hepatic Artery Embolizations
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Pfizer
Active, not recruiting - verified May 2010 -
Erlotinib and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
Posted: November 8th, 2006, 9:00am CST
Condition: Cancer
Interventions: Biological: cetuximab; Drug: erlotinib hydrochloride; Genetic: proteomic profiling; Other: laboratory biomarker analysis
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2009 -
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
Posted: April 5th, 2006, 9:00am CDT
Condition: Cancer
Interventions: Biological: recombinant interferon alfa-2b; Drug: sodium stibogluconate
Sponsors: The Cleveland Clinic; National Cancer Institute (NCI)
Recruiting - verified June 2007 -
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer
Posted: March 15th, 2006, 9:00am CST
Conditions: Breast Cancer; Cognitive/Functional Effects; Colorectal Cancer; Lung Cancer; Pain; Prostate Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: psychosocial assessment and care
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified August 2009 -
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Posted: November 9th, 2004, 9:00am CST
Condition: Cancer
Interventions: Drug: isolated perfusion; Drug: melphalan
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - verified July 2009 -
CCI-779 in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Posted: October 6th, 2004, 9:00am CDT
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Lung Cancer; Neoplastic Syndrome
Intervention: Drug: temsirolimus
Sponsors: Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Active, not recruiting - verified January 2006 -
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Posted: January 9th, 2004, 9:00am CST
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
Intervention: Drug: gefitinib
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Active, not recruiting - verified July 2010 -
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
Posted: August 6th, 2003, 9:00am CDT
Condition: Cancer
Intervention: Biological: recombinant adenovirus-hIFN-beta
Sponsors: Abramson Cancer Center of the University of Pennsylvania; National Cancer Institute (NCI)
Active, not recruiting - verified December 2005 -
EPO906 in Carcinoid and Other Neuroendocrine Tumors
Posted: December 4th, 2002, 9:00am CST
Conditions: Carcinoid; Neuroendocrine Tumors
Intervention: Drug: EPO906 epothilone B
Sponsor: Novartis Pharmaceuticals
Completed - verified August 2010 -
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Posted: November 12th, 2002, 9:00am CST
Condition: Cancer
Interventions: Drug: docetaxel; Drug: thalidomide
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Completed - verified June 2010 -
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Posted: September 13th, 2001, 9:00am CDT
Conditions: Lung Cancer; Malignant Mesothelioma; Metastatic Cancer; Thymoma and Thymic Carcinoma
Intervention: Procedure: radiofrequency ablation
Sponsors: University of California, Los Angeles; National Cancer Institute (NCI)
Active, not recruiting - verified July 2010 -
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
Posted: July 11th, 2001, 9:00am CDT
Condition: Cancer
Intervention: Drug: entinostat
Sponsor: National Cancer Institute (NCI)
Completed - verified February 2007 -
Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
Posted: July 11th, 2001, 9:00am CDT
Conditions: Lung Cancer; Malignant Mesothelioma; Metastatic Cancer
Intervention: Drug: doxorubicin hydrochloride
Sponsor: National Cancer Institute (NCI)
Completed - verified May 2002 -
Interleukin-12 in Treating Patients With Cancer in the Abdomen
Posted: November 1st, 1999, 9:00am CST
Conditions: Anal Cancer; Colorectal Cancer; Gallbladder Cancer; Gastric Cancer; Pancreatic Cancer
Intervention: Biological: Recombinant Interleukin-12
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Completed - verified August 2010